Loading
CAR-T Cell Therapy Research / Protein Degradation and Inhibitors / Monoclonal and Polyclonal Antibodies Research · Journal article
Nature Communications · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical proof-of-concept study identifying MPZL1, an amplified surface protein in up to 75% of certain solid tumors, as a candidate CAR-T cell target. In vitro and animal models demonstrate selective CAR-T activity against MPZL1-positive cancer cells. The work is hypothesis-generating and establishes a framework for surface protein-based CAR-T targeting but does not provide clinical evidence of efficacy or safety.
Preclinical target discovery and CAR-T engineering; in vitro, xenograft, autochthonous mouse, and patient-derived tissue explant models. In vitro cancer cell lines, human xenograft models, autochthonous mouse models, and patient-derived tissue explants; specific cell types, tumor lineages, and patient cohort sizes not detailed in abstract.. Intervention: Monoclonal antibody targeting MPZL1's extracellular domain and engineered CAR-T cells targeting MPZL1-positive cancer cells.
MPZL1 is amplified in up to 75% of patients with certain solid tumor types MPZL1 is abundantly expressed on surface tumor cells across diverse cancer types and largely absent from healthy tissues Engineered CAR-T cells selectively eliminate MPZL1-positive cancer cells in vitro and in human xenograft, autochthonous mouse, and patient-derived tissue explant preclinical models
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies a potentially targetable surface antigen for CAR-T therapy in a subset of solid tumors, but clinical translation requires first-in-human trials to establish safety, tolerability, and efficacy. The framework may guide future CAR-T target discovery based on amplified surface proteins.
This is preclinical target discovery and validation work using in vitro and animal models; it establishes MPZL1 as a candidate CAR-T target but does not present clinical efficacy data or human trials.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies a potentially targetable surface antigen for CAR-T therapy in a subset of solid tumors, but clinical translation requires first-in-human trials to establish safety, tolerability, and efficacy. The framework may guide future CAR-T target discovery based on amplified surface proteins.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Most cancer therapies target genetic alterations driving tumor growth, but many drivers are undruggable or rare, limiting their therapeutic reach. Here, we demonstrate that amplified genes encoding cell surface proteins provide a rich, cancer-driver–agnostic source of targets. We identify MPZL1 (myelin protein zero–like 1), amplified in up to 75% of patients with certain solid tumor types, as abundantly expressed on the surface tumor cells across diverse cancer types while being largely absent from healthy tissues, offering a favorable therapeutic window. We develop a monoclonal antibody targeting MPZL1’s extracellular domain and engineer chimeric antigen receptor (CAR)-T cells that selectively eliminate MPZL1-positive cancer cells in vitro. These CAR-T cells exhibit antitumor activity in human xenograft, autochthonous mouse, and patient-derived tissue explant preclinical models. This work establishes MPZL1 as a viable CAR-T cell target and provides a generalizable framework for exploiting amplified cell surface receptors as broadly applicable therapeutic targets.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.